IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis

KAISA GRANFORS,1 AND AULI TOIVANEN2

From the Departments of 1Medical Microbiology and 2Medicine, Turku University, Turku, Finland

SUMMARY Patients who develop reactive arthritis after yersinia enteritis are characterised by high and persisting IgA-anti-yersinia antibodies. We have further analysed the humoral immune response to yersinia in this condition. Total concentrations of IgM, IgG, IgA, and secretory IgA in the serum and specific anti-yersinia antibodies belonging to IgA1, IgA2, or secretory IgA were compared in patients with or without reactive arthritis. In the former group the serum concentration of secretory IgA and of yersinia specific antibodies in all categories studied was raised compared with the level in patients without joint symptoms; the difference was most significant for the IgA-anti-yersinia antibodies with secretory piece or with J chain. The findings suggest that the strong antibody response in the patients developing reactive arthritis is due to a chronic stimulation of the intestinal lymphoid tissue.

The most common symptoms of yersinia infection are fever, abdominal pain, and gastroenteritis.1,2 The disease is often mild and may even pass unnoticed. One to three weeks after the initial phase, however, postinfection complications such as eye inflammation or arthritis may develop. Yersinia triggered reactive arthritis varies in severity from slight arthralgias to severe polyarthropathies and in duration from a few days to several months; in some cases chronic arthropathies develop.3–6

In the pathogenesis of yersinia triggered reactive arthritis the micro-organism is the main causative factor, and some strains of yersinia are especially prone to give rise to postinfection complications.7 Host related factors are also of obvious importance. The risk of complications is much increased in persons with HLA-B27.3–8 Also, the immune response of patients developing reactive arthritis differs from that in persons who recover from a yersinia infection without complications. Thus the proliferative response of lymphocytes to yersinia or Escherichia coli is weaker in patients with arthritis despite otherwise normal cell mediated immune competence.9–11 Patients with arthritis tend in the initial phase to have a weak antibody response of IgM class against yersinia, but later they show a strong and persisting IgG and especially IgA response, which may even last for years after the actual disease; the serum levels of IgA antibodies to yersinia seem to correlate with the severity of the arthritis.12 13

The strong IgA response to yersinia in arthritic patients is an interesting phenomenon since the half life of IgA is only a few days14; therefore the persistence of yersinia specific IgA suggests prolonged stimulation and continuous antibody production. It is an open question where this production takes place. We have approached the question by quantifying separately the IgA1, IgA2, and secretory IgA antibodies to yersinia in patients with or without reactive arthritis after yersinia enteritis. The results obtained suggest strongly that substantial production of the anti-yersinia antibodies in patients with reactive arthritis takes place locally in the intestinal mucosa or close to it.

Patients and methods

PATIENTS A total of 125 serum samples from 42 patients with yersinia infection was studied. Yersinia enterocolitica serotype O:3 infection was diagnosed on the basis of bacteriological or serological findings, or both, and the typical clinical picture. The patients were divided into two groups according to their arthritic symptoms. Eighteen patients developed arthritis after yersinia infection. All of them had clearly demonstrable joint effusion in at least one joint.

Accepted for publication 28 January 1986.
Correspondence to Dr Kaisa Granfors, Department of Medical Microbiology, Turku University, SF–20520 Turku, Finland.
Twenty four had no arthritic symptoms. Serum samples were collected from the patients, starting from the beginning of the infection. The follow up periods ranged from two to 12 months after onset of the infection, with a mean interval of 1-3 months between the samples. All samples were stored at −20°C and studied at the same time.

ELISA FOR YERSINIA ANTIBODIES CONTAINING SECRETORY COMPONENT AND J CHAIN
Antibodies to yersinia containing secretory component and J chain were measured by an enzyme linked immunosorbent assay using the same principle as described earlier for IgM, IgG, and IgA class yersinia antibodies.\(^\text{12}\) In brief, yersinia antigens were adsorbed onto polystyrene microtitre plates (Linbro, Titertek, Linbro Division, Flow Laboratories, Hamden, Conn.); 75 µl of serum dilutions (1:100) were added to the plates and incubated at 37°C for two hours. The plates were washed three times with saline containing 0.05% Tween 20, and 75 µl of rabbit immunoglobulins to human secretory component (fluorescein isothiocyanate conjugated, DAKO Patts A/S, Copenhagen, Denmark) in dilution 1:300 or to human J chain (Nordic Immunological Laboratories, Tilburg, Netherlands) in dilution 1:1500 was added. After incubation overnight at room temperature washing was carried out as previously, and alkaline phosphatase conjugated swine antirabbit IgG (Orion Diagnostica, Espoo, Finland) was added in dilution 1:400 and incubated at 37°C for five hours. After three repeated washings 75 µl fresh substrate (1 mg of the disodium salt of p-nitrophenyl phosphate/ml of diethanolamine-MgCl\(_2\) buffer solution; Orion Diagnostica) was added to the plates, which were then incubated for 30 min at 37°C; 120 µl of 1 M NaOH was added to stop the reaction. The optical absorbance was measured by a specially designed photometer (Titertek/Multiskan, Eflab, Helsinki, Finland) at a wavelength of 405 nm. The results were evaluated by means of standard sera containing high concentrations of the corresponding yersinia antibodies. The concentration of antibodies in the sample was expressed as relative units (EU), where one unit was 1/100 of the corresponding antibody concentration in the reference serum.

ELISA FOR IgA1 AND IgA2 YERSINIA ANTIBODIES
For the measurement of IgA1 and IgA2 antibodies to yersinia monoclonal antibodies against the two IgA subclasses were used in an ELISA with yersinia antigen. After incubation of serum dilutions (1:100) on yersinia antigen coated plates monoclonal antibody against IgA1 or IgA2 (Becton and Dickinson Co., Sunnyvale, California; clone 1–155–1, code No 5100 and clone 14–3–26, code 5110 respectively) was added onto the plates separately at a dilution of 1:500. After incubation and washing rabbit FITC conjugated antimouse immunoglobulin (Miles-Yeda, Kiryat Weizmann, Rehovot, Israel) absorbed with human IgG was added at a dilution of 1:2000 and incubated for three hours. After washing alkaline phosphatase conjugated swine antirabbit IgG (Orion Diganostica) was added and the enzyme reaction was allowed to occur as described before. The results were evaluated by means of standard sera as described above for secretory IgA antibodies.

TOTAL IgM, IgG, AND IgA
Total serum IgM, IgG, and IgA were measured with Tripartigen plates (Behringwerke, Marburg, West Germany).

QUANTIFICATION OF TOTAL SECRETORY IgA
The total amount of secretory IgA was determined by an ELISA. Polystyrene microtitre plates (Linbro) were coated with antihuman IgA (Cappel Laboratories, Cochranville, Pennsylvania, USA). After incubation overnight the antibody solution was emptied from the wells and the samples to be assayed, diluted 1:50 in 1% normal sheep serum/PBS, were incubated in the plates for two hours at 37°C. Washing was carried out three times as above, and rabbit immunoglobulins to the human secretory component (FITC conjugated, DAKO Patts A/S) were added in dilution 1:300. After incubation overnight at room temperature washing was carried out as previously and alkaline phosphatase conjugated swine antirabbit IgG (Orion Diagnostica) was added in dilution 1:400 and incubated at 37°C for five hours. After washing substrate was added, absorbances measured, and results evaluated by means of the standard serum as described above for secretory IgA yersinia antibodies.

TESTING THE SPECIFICITY OF THE ANTISECRETORY PIECE REAGENT
The key issue in evaluating the results is the specificity of the antisera used as detecting reagents, and therefore they were tested extensively. We were especially concerned about the possibility that the antisecretory piece reagent might also pick up antyersinia antibodies of monomeric IgA. This was ruled out by testing the specificity of the antisecretory piece reagent in the following way. Serum samples from four patients giving a positive reaction in an ELISA for IgM, IgG, and IgA yersinia
antibodies and for secretory IgA yersinia antibodies were centrifuged in sucrose density gradients (5-40% sucrose) at 156 000 g for 16 hours (Beckman, model L2-65B). Twenty eight fractions collected through the bottom of the tubes were quantified by an ELISA separately for IgM, IgG, IgA, and secretory IgA antibodies to yersinia. Measurement of IgM, IgG, IgA, and secretory IgA antibodies to yersinia in each fraction showed different sedimentation constants characteristic for each of them. The antisecretory piece reagent gave a peak between IgM and IgA, characteristic for polymeric IgA. No reactivity with this reagent was seen in the area of peaks of IgM, IgG, or IgA. The FITC conjugated antisecretory piece reagent (DAKO Patts A/S, Copenhagen, Denmark) was the only one out of six antisecretory piece reagents available which was specific for polymeric IgA. All unconjugated reagents tested reacted also with monomeric IgA. The presence of the FITC label did not disturb our ELISA.

Results

**TOTAL IMMUNOGLOBULIN**

The total concentrations of serum IgM and IgG were similar in both patient groups (Table 1). The total concentrations of serum IgA were slightly higher in patients with reactive arthritis, but the difference was not statistically significant. When the secretory IgA was analysed separately the difference between these two patient groups was clear: in arthritic patients the concentration was 86.8±12.2 EIU (mean±SEM) and in those without arthritis 36.2±19.5 EIU (p<0.05, χ² test).

**YERSINIA ANTIBODIES**

The concentrations of yersinia specific antibodies belonging to secretory IgA, molecules containing J chain, IgA1, or IgA2 are given in Table 2. A similar difference between the two patient groups is clearly seen regarding them all: those with reactive arthritis have higher levels of yersinia specific antibodies. In patients with arthritis the level of yersinia specific secretory IgA was 229±15 EIU as compared with 61±10 EIU in patients without joint symptoms (p<0.005). The respective values for the molecules with the J chain were 265±15 EIU and 80±11 EIU (p<0.005). The same tendency was also evident with yersinia specific IgA1 and IgA2, but the differences between the two patient groups were not statistically significant (Table 2).

**Table 1**  The highest IgM, IgG, IgA, and secretory IgA concentrations measured during the follow up in sera of patients after Y enterocolitica O:3 infection, according to the presence of arthritis

<table>
<thead>
<tr>
<th>Arthritis</th>
<th>IgM (mg/ml)</th>
<th>IgG (mg/ml)</th>
<th>IgA (mg/ml)</th>
<th>Secretory IgA (EIU)</th>
<th>No of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>2.3±0.4</td>
<td>14.6±0.5</td>
<td>3.1±0.3</td>
<td>36.2±19.5</td>
<td>11</td>
</tr>
<tr>
<td>Yes</td>
<td>2.2±0.3</td>
<td>16.9±0.9</td>
<td>4.0±0.3</td>
<td>86.8±12.2</td>
<td>15</td>
</tr>
<tr>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>p&lt;0.05</td>
<td></td>
</tr>
</tbody>
</table>

*Values are mean ± SEM. NS= not significant.

**Table 2**  The highest concentrations of yersinia specific antibodies belonging to secretory IgA, J chain containing antibodies, IgA1, or IgA2 measured during the follow up in sera of patients after Y enterocolitica O:3 infection, according to the presence of arthritis

<table>
<thead>
<tr>
<th>Arthritis</th>
<th>Yersinia antibodies (EIU)</th>
<th>No of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>slgA</td>
<td>J chain</td>
</tr>
<tr>
<td>No</td>
<td>61±10</td>
<td>80±11</td>
</tr>
<tr>
<td>Yes</td>
<td>229±15</td>
<td>265±15</td>
</tr>
<tr>
<td>p&lt;0.005</td>
<td>p&lt;0.005</td>
<td>NS</td>
</tr>
</tbody>
</table>

*EIUs in different columns are not comparable with each other.

Values are mean±SEM.

NS=not significant.

Discussion

Our results show that the strong IgA-anti-yersinia response characteristic for patients with reactive arthritis after yersinia infection is seen especially clearly in the secretory IgA. The mean concentrations of IgA-anti-yersinia antibodies over the range of samples from each patient show higher values in arthritic patients. The highest concentrations are usually recorded at the beginning of the disease, and the difference is significant. This becomes even more clear later when IgA class antibodies have disappeared from the sera of patients with uncomplicated disease but persist in sera of patients with arthritis. The same situation is seen in secretory IgA class yersinia antibodies and, further, the difference is almost as significant for IgG class antibodies. The persistence and strength of IgA response in reactive arthritis is in line with observations indicating that in complicated brucella infections high levels of anti-brucella antibodies of IgG and IgA class appear. A question arises whether their occurrence is linked to impaired bacterial elimination; circulating IgA class antibodies have been found to block the bactericidal effect of IgG and IgM antibodies.
During recent years IgA has been linked in several ways to various rheumatic diseases. In rheumatoid arthritis early appearance of IgA rheumatoid factor has been reported to indicate a poor prognosis, and IgA rheumatoid factor has a close association with fluctuations in disease activity. Furthermore, raised levels of IgA in the sera of patients with rheumatoid arthritis are frequently seen; some of it is complexed covalently to the α1 antitrypsin, a major antiprotease. It has been suggested that production of abnormal thiol reactive IgA may be a critical dysfunction of the humoral immune response in the pathogenesis of rheumatoid arthritis. Several reports indicate that in ankylosing spondylitis—a disease often linked with reactive arthritis and often seen in persons possessing HLA-B27—raised serum IgA levels are seen; IgA concentrations both in serum and in secretions correlate with the disease activity, and patients with ankylosing spondylitis may also have an increased level of IgA-anti-keratiella antibodies. Recently, increased levels of IgA have been reported also in Reiter’s disease in the presence of normal IgG and IgM levels.

Considering all these observations a few facts have to be kept in mind. Firstly, the half life of IgA is short, only a few days, and therefore the persistence of antibodies must depend on prolonged synthesis. This raises the question about a persisting antigen or a cross reaction between yersinia and the host structures, possibly HLA-B27. If either of these possibilities were true, the next question would be where the antigenic structure would operate; the site of origin of the antibodies might offer a clue.

The observations by Vuento et al indicate that the increase of IgA-anti-yersinia antibodies is probably not due to increased antibody production by circulating peripheral blood lymphoid cells. These authors stimulated mononuclear cells from peripheral blood with yersinia or pokeweed mitogen in vitro and measured the various immunoglobulins produced; no difference between patients with or without reactive arthritis could be observed. Nikkin et al also point out that in patients with ankylosing spondylitis no increase in the circulating IgA bearing lymphocytes is seen despite raised serum IgA.

Secondly, certain facts about the production of IgA subclasses and of secretory IgA should be considered. Normally serum IgA consists of 80–100% IgA1 and only 0–20% IgA2, whereas mucosal plasma cells produce IgA1 and IgA2 in secretions in almost equal amounts. In secretions the IgA molecules are mainly dimeric, i.e., two IgA monomers are held together by a J chain, to which dimer the secretory component is associated when the molecule passes through the epithelial cells. Therefore, the presence of IgA2 subclass and secretory component in IgA may be considered markers of mucosal origin. Our present and earlier results do not permit a comparison of the absolute amounts of the different IgA antibodies. A comparison in each category between arthritic and non-arthritic patients is possible, however, and shows an interesting sequence in the statistical significances. The groups differ only slightly when the serum concentration of total IgA is compared, but for total secretory IgA the difference is statistically significant. When specific IgA-anti-yersinia antibodies are compared the patients with arthritis have significantly higher values than the non-arthritic ones. If, further, the quite small fractions represented by the yersinia specific antibodies with J chain or belonging to secretory IgA are compared in the two patient groups a highly significant difference is seen. The fact that IgM and IgA both contain J chain should be kept in mind. Since arthritic patients have lower concentrations of IgM class antibodies to yersinia than the patients without arthritis, however, it is obvious that the difference in yersinia antibodies containing J chain between arthritic and non-arthritic patients is mostly due to polymeric IgA antibodies.

The increased and persisting production of IgA-anti-yersinia antibodies is reflected in all categories of IgA studied, but most clearly in secretory IgA. This indicates that at a location close to the intestinal mucosa or within it a mechanism must be operating which chronically stimulates the antibody response and also leads to a leakage of the secretory IgA into the serum; the same or a similar mechanism may also operate at other locations where IgA is synthesised. This fits well with the fact that yersinia may cause strong stimulation of the lymphoid elements close to the terminal ileum and cecum, and in the mesenteric lymph nodes.

These studies were supported by grants from the Sigrid Jusélius Foundation, the Yrjö Jahnsson Foundation, and the US Public Health Service (No I RO 1 AM 33311, awarded by National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases).

References
IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis


IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis.

K Granfors and A Toivanen

*Ann Rheum Dis* 1986 45: 561-565
doi: 10.1136/ard.45.7.561

Updated information and services can be found at:

[http://ard.bmj.com/content/45/7/561](http://ard.bmj.com/content/45/7/561)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)